USPTO serial 85639079
PILLIE
Reviewed by CopyMark Law Group
Reg. 4394743Status 710
- Filing date
- Status date
- Registration date
- Sep 3, 2013
- Examiner
- JOINER, KATINA JACKSON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PILLIE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Neha Jaiswal
NEHA JAISWAL LAW OFFICE OF NEHA JAISWAL405 ENCLAVE CIR APT 209COSTA MESA, CA 92626-8121UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Dietary and nutritional supplements; Dietary and nutritional supplements containing a vitamin, a mineral, an herb or other botanical extract; an amino acid for nutritional purposes; dietary concentrate, metabolite, constituent or extract for use by man to supplement the diet by increasing the total dietary intake; Dietary supplements for human consumption; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Herbal supplements; Natural herbal supplements; Nutraceuticals for use as a dietary supplement for Gastrointestinal, Digestive and liver support; Vitamin and mineral supplements for respiratory system support; dietary supplements for Mood, sleep, memory support; dietary supplements for Central and peripheral nervous system support; dietary supplements for Vision support, Hearing support, Cardiovascular support, Metabolic support; dietary supplements for Bone, joint and muscle support; dietary supplements for Dermatologic support and Anti-aging support; nutritional supplements for Beauty, namely, hair, skin, nails support; dietary supplements for Hormone and endocrine support, Weight management/support, Blood sugar support, Energy support, Immune support, Respiratory support, Men's health and Women's health; dietary supplements for Exercise and physical performance support; dietary supplements for Infant, toddler, children nutritional support; dietary supplements for Geriatric health and support; dietary supplements for Urinary support; Natural Product Extracts in the nature of plant extracts for medical purposes; dietary supplements for Anti-inflammatory support; dietary supplements for Lipid support and Anti-oxidant support; dietary and nutritional supplements containing Greens, Fibers, Fruits, Vegetables, and superfoods; dietary Fibers for treating constipation; fruit-based Meal replacement bars for medical purposes; Amino Acids for nutritional purposes; Nutritional supplements, namely, carbohydrates in powdered form; Protein and peptide formulas for use as dietary and nutritional supplements; Prebiotics/Probiotics; Nutritional supplements in the form of solid dosage forms, semi-solid dosage forms, liquid dosage forms and parenteral dosage forms; Pharmaceutical preparations for Alzheimer's Dementia treatment; pharmaceutical preparations in the nature of Amoebicides/Antiprotozoals; Anabolic/Androgenic Steroids; Analeptic drugs; Analgesics/Anti-pyretics; Anesthetic Agent for surgical and non-surgical use; Antacids/Antiflatulents; pharmaceutical preparations, namely, Anthelmintics; Anti-Arthritis preparations; Anti-Inflammatory Drugs; Anti-Tuberculosis Drugs; Anti-acne/Anti-psoriatic Drugs; Anti-allergic Drugs; Antibiotics/Antibacterials; Anticancer Drugs; Anti-coagulant and Antithrombotic Agents; pharmaceutical preparations, namely, Anti-convulsants; pharmaceutical preparations, namely, Anti-depressants; Anti-diabetic drugs; Antidiarrheals; pharmaceutical preparations in the nature of Anti-emetics; Anti-epileptic pharmaceutical preparations; Anti-fungal preparations; Antiinfectives; Anti-malarials; Anti-migraine Drugs; Antiobesity Drugs; Anti-osteoporotic Agents; Anti-Parkinson's drugs; Anti-psychotic drugs; Anti-retroviral drugs; Anti-spasmodics drugs; Antitussive drugs; pharmaceutical preparations, namely, Anti-ulcerants; Antivirals; Anxiolytics/Sedatives; Appetite Stimulants; Benign Prostatic Hyperplasia Drugs; Biologics and Biosimilars for the treatment of respiratory diseases; pharmaceuticals in the nature of Birth Control preparations; pharmaceuticals in the nature of Cardiovascular Agents; Cognitive and ADHD drugs; pharmaceutical preparations in the nature of cholesterol and Hypolipedemic Agents; pharmaceutical preparations for Cough and Cold treatment; Diuretics; Electrolyte Solutions for the treatment of respiratory diseases, namely, cough, cold, and asthma; pharmaceuticals for Erectile Dysfunction Therapy; Expectorants/Cold Preparations/Mucolytes; pharmaceuticals in the nature of Eye and Ear Preparations; pharmaceuticals for the treatment of Gastroenterology issues; pharmaceuticals in the nature of Glucose solutions for the treatment of respiratory diseases; pharmaceuticals, namely, Gout Preparations; pharmaceuticals, namely, Haematinic Preparation; pharmaceuticals, namely, Haemorrhoelogic Agents; pharmaceuticals, namely, Haemostatics; pharmaceutical preparations for Hormone Treatment; pharmaceuticals, namely, Hormone Replacement Therapy; pharmaceutical preparations for Inflammation and Immunology; pharmaceuticals, namely, Immunosuppressants; Inhaler drugs for the treatment of respiratory diseases; Intranasal agents for the treatment of respiratory diseases; Intravenous drugs for the treatment of respiratory diseases; Iron Chelators; pharmaceuticals for the treatment of Irritable Bowel Syndrome; Nasal Preparations for the treatment of respiratory diseases; pharmaceutical preparations in the nature of Non-steroidal anti-inflammatory agents for the treatment of respiratory disease; OTC drugs for the treatment of respiratory diseases; Otic drugs for the treatment of respiratory diseases; Ophthalmologic drugs and preparations; pharmaceutical preparations for Pain Treatment; pharmaceutical preparations for Palliative Treatment; Poison antidotes; Psychiatric and psychotropic drugs; Respiratory Drugs, namely, pharmaceutical products for treating respiratory diseases; Saline Solutions for medical purposes; Sedative/Hypnotics; Small Molecule drugs for the treatment of respiratory diseases; Skeletal Muscle Relaxant; pharmaceutical preparations for the treatment of Sexually transmitted diseases; Suppository drugs; Systemic Corticosteroids; Topical Anti- Infectives; Topical Corticosteroids; Topical Preparations for the treatment of respiratory diseases; pharmaceutical preparations in the nature of Urinary Smooth Muscle Contractor; Urinary Smooth Muscle Relaxants; Uterine Stimulants; Vaccines; Vertigo Treatments; Vitamins and Mineral drugs, solutions and preparations; Wart Treatments | SECTION 8 - CANCELLED | May 29, 2012 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 5, 2020 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Sep 3, 2018 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 3, 2013 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 18, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 18, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 29, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 13, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 6, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 2, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 1, 2013 | ALIE | ASSIGNED TO LIE | — |
| Mar 30, 2013 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Mar 30, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 30, 2013 | PETG | PETITION TO REVIVE-GRANTED | — |
| Mar 30, 2013 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Sep 24, 2012 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2012 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 24, 2012 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 17, 2012 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 8, 2012 | MDSC | NOTICE OF DESIGN SEARCH CODE MAILED | — |
| Jun 7, 2012 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 2, 2012 | NWAP | NEW APPLICATION ENTERED | — |